BR112023017461A2 - Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco - Google Patents
Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíacoInfo
- Publication number
- BR112023017461A2 BR112023017461A2 BR112023017461A BR112023017461A BR112023017461A2 BR 112023017461 A2 BR112023017461 A2 BR 112023017461A2 BR 112023017461 A BR112023017461 A BR 112023017461A BR 112023017461 A BR112023017461 A BR 112023017461A BR 112023017461 A2 BR112023017461 A2 BR 112023017461A2
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- condition
- left ventricular
- cavity
- cardiac
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000002861 ventricular Effects 0.000 title abstract 4
- 230000000747 cardiac effect Effects 0.000 title abstract 2
- 230000009787 cardiac fibrosis Effects 0.000 title abstract 2
- 230000008602 contraction Effects 0.000 title abstract 2
- 208000007345 glycogen storage disease Diseases 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 210000005240 left ventricle Anatomy 0.000 title abstract 2
- 201000006938 muscular dystrophy Diseases 0.000 title abstract 2
- 208000031225 myocardial ischemia Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000002235 sarcomere Anatomy 0.000 title abstract 2
- 230000008719 thickening Effects 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156853P | 2021-03-04 | 2021-03-04 | |
| PCT/US2022/018725 WO2022187501A1 (en) | 2021-03-04 | 2022-03-03 | Cardiac sarcomere inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017461A2 true BR112023017461A2 (pt) | 2023-09-26 |
Family
ID=80937093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017461A BR112023017461A2 (pt) | 2021-03-04 | 2022-03-03 | Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11919909B2 (https=) |
| EP (1) | EP4301760A1 (https=) |
| JP (1) | JP7850737B2 (https=) |
| KR (1) | KR20240015622A (https=) |
| CN (1) | CN117083275A (https=) |
| AR (1) | AR125026A1 (https=) |
| AU (1) | AU2022229390A1 (https=) |
| BR (1) | BR112023017461A2 (https=) |
| CA (1) | CA3209557A1 (https=) |
| CL (2) | CL2023002616A1 (https=) |
| IL (1) | IL305628A (https=) |
| MX (1) | MX2023010125A (https=) |
| TW (1) | TW202302594A (https=) |
| WO (1) | WO2022187501A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) * | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| RS67793B1 (sr) * | 2022-09-02 | 2026-03-31 | Cytokinetics Inc | Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| ATE552236T1 (de) | 2003-01-14 | 2012-04-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
| EP1605752B1 (en) | 2003-03-27 | 2011-09-14 | Cytokinetics, Inc. | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. |
| EP1621540A4 (en) | 2003-04-21 | 2008-07-23 | Ono Pharmaceutical Co | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF |
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| TW200718692A (en) | 2005-04-22 | 2007-05-16 | Wyeth Corp | Dihydrobenzofuran derivatives and uses thereof |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| NZ596302A (en) | 2009-05-15 | 2014-01-31 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US9409917B2 (en) | 2012-01-20 | 2016-08-09 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| CN104539229A (zh) | 2014-12-26 | 2015-04-22 | 金海新源电气江苏有限公司 | 一种太阳能光伏支架 |
| EP4234017B1 (en) | 2015-01-22 | 2026-04-15 | MyoKardia, Inc. | Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) |
| JP2019507110A (ja) | 2015-12-17 | 2019-03-14 | シンジェンタ パーティシペーションズ アーゲー | 殺微生物性オキサジアゾール誘導体 |
| CN108368098B (zh) | 2015-12-18 | 2022-01-28 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| CA3022432A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| WO2017222951A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| JP6681517B2 (ja) | 2016-09-27 | 2020-04-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| CA3071948A1 (en) | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| EA202191152A1 (ru) | 2018-10-29 | 2022-01-19 | Миокардиа, Инк. | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона |
| RS65302B1 (sr) | 2019-07-17 | 2024-04-30 | Cytokinetics Inc | Oralne formulacije inhibitora srčanog sarkomera |
| EP3999180B1 (en) | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| EP4054588A4 (en) | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843B (zh) | 2020-11-19 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN116507621B (zh) | 2020-11-24 | 2025-10-17 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| CN114539229B (zh) | 2020-11-24 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| TWI820622B (zh) | 2021-03-04 | 2023-11-01 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| RS67793B1 (sr) | 2022-09-02 | 2026-03-31 | Cytokinetics Inc | Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida |
-
2022
- 2022-03-03 CN CN202280017911.8A patent/CN117083275A/zh active Pending
- 2022-03-03 US US17/685,778 patent/US11919909B2/en active Active
- 2022-03-03 BR BR112023017461A patent/BR112023017461A2/pt unknown
- 2022-03-03 MX MX2023010125A patent/MX2023010125A/es unknown
- 2022-03-03 EP EP22712689.3A patent/EP4301760A1/en active Pending
- 2022-03-03 JP JP2023553393A patent/JP7850737B2/ja active Active
- 2022-03-03 KR KR1020237033052A patent/KR20240015622A/ko active Pending
- 2022-03-03 AU AU2022229390A patent/AU2022229390A1/en active Pending
- 2022-03-03 CA CA3209557A patent/CA3209557A1/en active Pending
- 2022-03-03 AR ARP220100486A patent/AR125026A1/es unknown
- 2022-03-03 WO PCT/US2022/018725 patent/WO2022187501A1/en not_active Ceased
- 2022-03-03 TW TW111107659A patent/TW202302594A/zh unknown
- 2022-03-03 IL IL305628A patent/IL305628A/en unknown
-
2023
- 2023-09-01 CL CL2023002616A patent/CL2023002616A1/es unknown
-
2024
- 2024-01-25 US US18/423,156 patent/US12286437B2/en active Active
- 2024-05-30 CL CL2024001620A patent/CL2024001620A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11919909B2 (en) | 2024-03-05 |
| JP7850737B2 (ja) | 2026-04-23 |
| US20220306642A1 (en) | 2022-09-29 |
| CL2024001620A1 (es) | 2024-11-04 |
| MX2023010125A (es) | 2023-09-11 |
| WO2022187501A1 (en) | 2022-09-09 |
| CN117083275A (zh) | 2023-11-17 |
| IL305628A (en) | 2023-11-01 |
| EP4301760A1 (en) | 2024-01-10 |
| CA3209557A1 (en) | 2022-09-09 |
| CL2023002616A1 (es) | 2024-02-02 |
| KR20240015622A (ko) | 2024-02-05 |
| JP2024508526A (ja) | 2024-02-27 |
| AU2022229390A1 (en) | 2023-09-21 |
| US12286437B2 (en) | 2025-04-29 |
| TW202302594A (zh) | 2023-01-16 |
| AR125026A1 (es) | 2023-05-31 |
| US20240309011A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023017461A2 (pt) | Compostos, composição farmacêutica, métodos de tratamento de doença cardíaca, de uma doença ou afecção associada à cardiomiopatia hipertrófica, de uma doença ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, de uma doença ou afecção associada à pequena cavidade ventricular esquerda e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, de uma doença ou afecção selecionada a partir de distrofias musculares e doenças de armazenamento de glicogênio, e, método de inibição do sarcômero cardíaco | |
| Wit et al. | Triggered activity and atrial fibrillation | |
| JP2012529486A5 (https=) | ||
| US9636327B2 (en) | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias | |
| US20160030452A1 (en) | Minocycline Derivatives | |
| JP2018528251A (ja) | 心房細動の予防及び治療のためのドフェチリドとメキシレチンの組合せ | |
| RU2018101439A (ru) | Метаболически устойчивые аналоги cyp-эйкозаноидов для лечения кардиологических заболеваний | |
| Whitaker | Anatomy of the heart | |
| SU1470190A3 (ru) | Способ получени 6-/4 @ -ацетил-2-метилимидазол-1-ил/-8-метил-2-/1Н/-карбостирила | |
| US11123328B2 (en) | Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction | |
| RU2485102C2 (ru) | Циклические индол-3-карбоксамиды, их получение и их применение в качестве лекарственных препаратов | |
| BR112022000474A2 (pt) | Formas polimórficas de (r)-4-(1-((3-(difluorometil)-1-metil-1h-pirazol-4-il)sulfonil)-1-fluoroetil)-n-(isoxazol-3-il)piperidina-1-carboxamida | |
| NO864514L (no) | Fremgangsmaate for fremstilling av nye thiazoloner. | |
| WO2025030135A3 (en) | Methods for treating and ameliorating angina and congestive heart failure | |
| EP2799430B1 (en) | Diphenylmethyl piperazine derivative and pharmaceutical composition using same | |
| Kausel et al. | Bradyarrhythmia as a presenting feature of subclinical hyperthyroidism | |
| JP2019535826A5 (https=) | ||
| Roque et al. | Ventricular tachycardia induced by pacing algorithm designed to avoid atrial fibrillation | |
| Kakavand et al. | Successful management of acute failure of the systemic right ventricle with cardiac resynchronization therapy | |
| Kamakura et al. | Efficacy of quinidine for suppressing Purkinje-related ventricular fibrillation in a patient with hypertrophic cardiomyopathy associated with midventricular obstruction | |
| van Middendorp et al. | Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts | |
| CN86107178A (zh) | 用作强心剂的芳酰基噻唑酮的制备方法 | |
| RU2442782C2 (ru) | Производные аминопиперидина как ингибиторы бпхэ (белка-переносчика холестерилового эфира) | |
| Vyas et al. | Coronary sinus as a site for stable temporary atrial pacing to tide over premature ventricular complex–triggered recurrent ventricular fibrillation in a patient with severe left ventricular dysfunction after coronary bypass surgery | |
| RU2345714C2 (ru) | Способ отбора больных хронической сердечной недостаточностью на бивентрикулярную электрокардиостимуляцию |